Physician profile
David Brian Moore
NPI 1609867688
$5,113.97
in general payments reported to CMS, 2019-2025
28 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,082 · 2020: $810 · 2021: $185 · 2022: $264 · 2023: $84.83 · 2024: $160 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb Sa | $1,588.56 | 2019 | |
| Livanova USA, INC. | $1,370.52 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Celgene Corporation | $529.72 | 2020 | |
| Abbvie INC. | $463.10 | 2021-2025 | |
| Allergan, INC. | $116.25 | 2019-2021 | |
| Sk Life Science, INC. | $110.07 | 2020-2025 | |
| Biogen, INC. | $105.86 | 2019-2025 | Vumerity, Tysabri |
| Eisai INC. | $95.40 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $94.36 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $68.10 | 2025 | Austedo Xr, Ajovy |
| Sunovion Pharmaceuticals INC. | $65.15 | 2019-2020 | |
| Lilly USA, LLC | $62.83 | 2024-2025 | Kisunla, Reyvow, Emgality |
| Neurelis, INC. | $50.53 | 2020-2021 | |
| Ceribell, INC. | $50.28 | 2025 | Pocket Eeg Device |
| Greenwich Biosciences, INC. | $49.73 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $49.32 | 2019-2024 | Fintepla |
| Jazz Pharmaceuticals INC. | $44.61 | 2019-2022 | |
| Medtronic, INC. | $41.36 | 2023 | Activa PC, Synchromedii |
| Lundbeck LLC | $40.32 | 2020-2025 | Vyepti |
| Genentech USA, INC. | $39.11 | 2025 | Ocrevus Zunovo |
| Emd Serono, INC. | $27.86 | 2019 | |
| Tanabe Pharma America, INC. | $15.43 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $13.29 | 2024 | |
| Zogenix INC. | $11.15 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.06 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.